# Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ofatumumab-a-fully-human-monoclonal-antibody-targeting-cd20-demonstrates/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Matthew J. Barth,Francisco J. Hernandez‐Ilizaliturri,Cory Mavis,Ping‐Chiao Tsai,John F. Gibbs,George Deeb,Myron S. Czuczman |
| Citations | 6 |
| DOI | 10.1182/blood.v116.21.3917.3917 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2565656247 |
| Type | article |
| Year | 2010 |

## Paper authors

- [Ping‐Chiao Tsai](https://scholariq.org/researchers/ping-chiao-tsai/)

## Paper journal

- [Blood](https://scholariq.org/journals/blood/)

## Paper primary topic

- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Paper topics

- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.